Prof. Nathan Fowler | ICML 2017 | Long-term follow-up of lenalidomide + rituximab in iNHL

Long-term follow-up of lenalidomide + rituximab in iNHL

Nathan Fowler | ASH 2018 | Long-term updates on lenalidomide plus rituximab in FL

Nathan Fowler from MD Anderson Cancer Center discusses long-term updates on lenalidomide plus rituximab in FL.

Nathan Fowler | ASH 2018 | Long-term updates on lenalidomide plus rituximab in FL

Nathan Fowler from MD Anderson Cancer Center discusses long-term updates on lenalidomide plus rituximab in FL.

Lenalidomide, rituximab, cyclophosphamide, and dexamethasone combination is tolerable and effective in previously untreated iNHL

The phase II trial investigated the feasibility and response to lenalidomide, rituximab, cyclophosphamide, and...

Lenalidomide, rituximab, cyclophosphamide, and dexamethasone combination is tolerable and effective in previously untreated iNHL

The phase II trial investigated the feasibility and response to...

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month

First Name

Last Name

I agree to the Lymphoma Hub Terms & Conditions